Homology Medicines (FIXX) Short Interest Ratio & Short Volume → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free FIXX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Homology Medicines Short Interest DataCurrent Short Volume338,700 sharesPrevious Short Volume322,300 sharesChange Vs. Previous Month+5.09%Dollar Volume Sold Short$311,604.00Short Interest Ratio / Days to Cover0.9Last Record DateFebruary 29, 2024Outstanding Shares58,130,000 sharesFloat Size41,980,000 sharesShort Percent of Float0.81%Today's Trading Volume22,300 sharesAverage Trading Volume390,307 sharesToday's Volume Vs. Average6% Short Selling Homology Medicines ? Sign up to receive the latest short interest report for Homology Medicines and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatFIXX Short Interest Over TimeFIXX Days to Cover Over TimeFIXX Percentage of Float Shorted Over Time Ad InvestorPlaceProof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…Go here now for full story. Homology Medicines Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/29/2024338,700 shares $311,604.00 +5.1%0.8%0.9 $0.92 2/15/2024322,300 shares $232,056.00 +2.2%0.8%0.9 $0.72 1/31/2024315,400 shares $211,318.00 +8.4%0.8%0.8 $0.67 1/15/2024291,100 shares $173,582.93 -4.9%0.7%0.9 $0.60 12/31/2023306,100 shares $186,108.80 -19.5%0.7%0.9 $0.61 12/15/2023380,000 shares $208,240.00 -14.3%0.9%1.2 $0.55 Get the Latest News and Ratings for FIXX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter. 11/30/2023443,300 shares $235,392.30 +48.9%1.1%1.4 $0.53 11/15/2023297,800 shares $262,034.22 -6.7%0.7%1 $0.88 10/31/2023319,000 shares $331,760.00 +4.0%0.8%2.1 $1.04 10/15/2023306,700 shares $337,370.00 +23.3%0.7%0.9 $1.10 9/30/2023248,700 shares $290,979.00 -11.2%0.6%0.7 $1.17 9/15/2023280,100 shares $327,717.00 +0.1%0.7%0.8 $1.17 8/31/2023279,700 shares $335,640.00 -10.5%0.7%0.8 $1.20 8/15/2023312,600 shares $375,120.00 -1.5%0.8%0.9 $1.20 7/31/2023317,500 shares $441,325.00 +11.1%0.8%1 $1.39 7/15/2023285,800 shares $271,510.00 +9.2%0.7%2.2 $0.95 6/30/2023261,800 shares $231,693.00 -14.2%0.6%2.3 $0.89 6/15/2023305,100 shares $305,100.00 +10.0%0.7%2.7 $1.00 5/31/2023277,500 shares $271,034.25 +3.2%0.7%1.9 $0.98 5/15/2023268,800 shares $274,176.00 -23.4%0.6%1.7 $1.02 4/30/2023351,000 shares $333,450.00 -14.4%0.7%2.3 $0.95 4/15/2023409,800 shares $422,094.00 -3.4%0.8%2.8 $1.03 3/31/2023424,400 shares $437,132.00 +22.4%0.8%2.8 $1.03 3/15/2023346,800 shares $350,268.00 -0.7%0.7%2.1 $1.01 2/28/2023349,200 shares $530,784.00 -13.7%0.8%2.7 $1.52 2/15/2023404,500 shares $598,660.00 -16.1%1.0%2.9 $1.48 1/31/2023482,200 shares $757,054.00 -12.3%1.2%3.1 $1.57 1/15/2023550,100 shares $902,164.00 -10.6%1.4%3.4 $1.64 12/30/2022615,100 shares $775,026.00 -10.4%1.5%3.6 $1.26 12/15/2022686,300 shares $1.03 million -13.4%1.7%3.8 $1.50 11/30/2022792,600 shares $1.22 million -25.9%1.9%4.2 $1.54 11/15/20221,070,000 shares $1.89 million -4.5%2.6%5.3 $1.77 10/31/20221,120,000 shares $1.67 million -4.3%2.8%5.9 $1.49 10/15/20221,170,000 shares $1.60 million -14.6%2.9%5.7 $1.37 9/30/20221,370,000 shares $2.21 million +22.3%3.4%6.6 $1.61 9/15/20221,120,000 shares $2.02 million +24.4%2.8%4 $1.80 8/31/2022900,300 shares $2.11 million +1.9%2.2%3 $2.34 8/15/2022883,800 shares $2.55 million -23.8%2.2%2.6 $2.89 7/31/20221,160,000 shares $2.49 million +14.9%2.9%3 $2.15 7/15/20221,010,000 shares $2.30 million -8.2%2.5%2.5 $2.28The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide FIXX Short Interest - Frequently Asked Questions What is Homology Medicines' current short interest? Short interest is the volume of Homology Medicines shares that have been sold short but have not yet been covered or closed out. As of February 29th, traders have sold 338,700 shares of FIXX short. 0.81% of Homology Medicines' shares are currently sold short. Learn More on Homology Medicines' current short interest. What is a good short interest ratio for Homology Medicines? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FIXX shares currently have a short interest ratio of 1.0. Learn More on Homology Medicines's short interest ratio. What is a good short interest percentage for Homology Medicines? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.81% of Homology Medicines' floating shares are currently sold short. Is Homology Medicines' short interest increasing or decreasing? Homology Medicines saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 338,700 shares, an increase of 5.1% from the previous total of 322,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Homology Medicines' float size? Homology Medicines currently has issued a total of 58,130,000 shares. Some of Homology Medicines' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Homology Medicines currently has a public float of 41,980,000 shares. How does Homology Medicines' short interest compare to its competitors? 0.81% of Homology Medicines' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Homology Medicines: Liquidia Co. (10.57%), Centessa Pharmaceuticals plc (2.14%), Innoviva, Inc. (18.46%), MacroGenics, Inc. (14.65%), Cassava Sciences, Inc. (29.69%), Tyra Biosciences, Inc. (13.78%), Immunome, Inc. (4.42%), Ocular Therapeutix, Inc. (9.47%), ABIVAX Société Anonyme (0.19%), ARS Pharmaceuticals, Inc. (14.44%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.39 billion), General Motors ($3.88 billion), Super Micro Computer, Inc. ($3.51 billion), Charter Communications, Inc. ($3.22 billion), Occidental Petroleum Co. ($3.13 billion), Tractor Supply ($2.76 billion), Coinbase Global, Inc. ($2.63 billion), Suncor Energy Inc. ($2.48 billion), Moderna, Inc. ($2.04 billion), and Royal Caribbean Cruises Ltd. ($1.87 billion). View all of the most shorted stocks. What does it mean to sell short Homology Medicines stock? Short selling FIXX is an investing strategy that aims to generate trading profit from Homology Medicines as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Homology Medicines? A short squeeze for Homology Medicines occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FIXX, which in turn drives the price of the stock up even further. How often is Homology Medicines' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FIXX, twice per month. The most recent reporting period available is February, 29 2024. More Short Interest Resources from MarketBeat Related Companies: LQDA Short Squeeze CNTA Short Squeeze INVA Short Squeeze MGNX Short Squeeze SAVA Short Squeeze TYRA Short Squeeze IMNM Short Squeeze OCUL Short Squeeze ABVX Short Squeeze SPRY Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FIXX) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings